secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001437749-23-023415
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene reports Q2 net loss of $25.1M; ALS NfL biomarker positive; cash $49.2M
----------------------------------------------------------------------------

- Net loss of $25.1M ($0.29 per share) versus $4.5M loss in Q2 2022; R&D down to $6.6M.
- Cash, equivalents and marketable securities $49.2M after $40M June public offering; potential $130M more from warrants.
- CNM-Au8 reduced plasma neurofilament light chain (NfL) vs placebo (p=0.04) in HEALEY ALS trial at 24 weeks.
- Phase 2 RESCUE ALS results published in Lancet eClinicalMedicine; preparing for FDA ALS regulatory meetings.
- NMSS grant funds Cohort 2 of REPAIR-MS for progressive MS; multiple near-term data announcements expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774923023415/0001437749-23-023415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774923023415/clnn20230602_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-023415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer